secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001104659-25-023216
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Biosciences FY2024 net loss $44.6M; FDA agrees on accelerated approval path for iopofosine I 131
--------------------------------------------------------------------------------

- Net loss of $44.6M ($1.22 basic EPS) vs $42.8M in 2023; cash $23.3M as of Dec 31, 2024.
- FDA aligned on regulatory path for accelerated approval of iopofosine I 131 in WM; confirmatory study (100/arm) expected to cost $40M-$45M.
- Phase 2 CLOVER-WaM data: ORR 83.6%, MRR 58.2% (exceeded FDA 20% endpoint).
- G&A expenses surged to $25.6M from $11.7M due to commercialization infrastructure; R&D $26.1M slightly down.
- IND cleared for Auger-emitting radioconjugate; alpha-emitting IND planned H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925023216/0001104659-25-023216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925023216/tm259072d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-023216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer